Mega Genomics Limited — Earnings Release 2025

Mar 20, 2026

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Mega Genomics Limited

美因基因有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 6667)

PROFIT WARNING

This announcement is made by Mega Genomics Limited (the "Company", together with its subsidiaries, the "Group") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "Board") of directors (the "Directors") of the Company wishes to inform the shareholders of the Company (the "Shareholders") and potential investors of the Company that, based on the preliminary assessment on the Group's unaudited consolidated management accounts for the year ended 31 December 2025 and the information currently available to the Board, the Group expects that (i) revenue for the year ended 31 December 2025 will be approximately RMB240.0 million to RMB250.0 million, compared with revenue of RMB 164.2 million for the year ended 31 December 2024; and (ii) profit attributable to owners of the Group for the year ended 31 December 2025 will be approximately RMB25.0 million to RMB28.0 million, compared with profit attributable to owners of the Group of approximately RMB45.0 million for the year ended 31 December 2024. The Group expects revenue to increase whilst profit to decrease, primarily for the following reasons:

(i) The Group effectively drove revenue growth by expanding its product range, diversifying its product portfolio and optimising its product mix; (ii) the Group recognized credit impairment losses and incurred expenses for resumption of trading.

---

The information contained in this announcement is based solely on the Board’s preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2025 and on the information available to the Board as at the date of this announcement. These accounts and information have not been reviewed, confirmed or audited by the Company’s auditors and/or audit committee and may be subject to adjustment. The Group is in the process of preparing and finalizing the Group’s annual results for the year ended 31 December 2025. Details of the financial information of the Group for the year ended 31 December 2025 will be disclosed in the annual results announcement which is expected to be published on 31 March 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Mega Genomics Limited
LIN Lin
Executive Director and Chairperson

Hong Kong, 20 March 2026

As at the date of this announcement, the executive Directors are Dr. Yu Rong, Ms. Lin Lin and Ms. Jiang Jing; the non-executive Director is Ms. Guo Meiling; and the independent non-executive Directors are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.

• For identification purpose only